Katie Kelley

Katie Kelley is a hepatobiliary cancer oncologist who contributed to the CELESTIAL trial establishing cabozantinib as a second- or third-line treatment for advanced HCC. Her research encompasses the tumor microenvironment of HCC, mechanisms of therapeutic resistance, and combinations of TKIs with immune checkpoint inhibitors. She investigates both HCC and biliary tract cancers, addressing FGFR2 and IDH inhibition in intrahepatic cholangiocarcinoma. She is principal investigator of multiple NCI-sponsored hepatobiliary cancer clinical trials at UCSF.